Welcome to the CED Clinic Weekly Literature Radar for October 09, 2026. This weekly index aggregates and translates 16 newly published biomedical studies, clinical trial protocols, open-access preprints, and health regulatory filings. By tracking multi-repository biomedical literature across PubMed, Europe PMC, ClinicalTrials.gov, and OpenAlex, CED Clinic provides patients, clinicians, and researchers with objective, evidence-grounded tracking of emerging science without overstating preliminary findings.

Each indexed report is examined for study design, sample size, quantified outcomes, and direct clinical applicability. Translating primary data into clear clinical perspectives empowers healthcare providers and patients to make informed, collaborative decisions about medical cannabis and related therapies.

Mainstream Media Claim: News reports frequently frame findings like “Efficacy and safety of cannabinoids in the treatment of spasticity in “ as immediate therapeutic breakthroughs or universal treatment warnings without context.

Primary PubMed / Journal Evidence: Analysis of published data in PubMed provides verified cohort measurements and specific outcome markers. Systematic trial evaluation demonstrates distinct endpoints that clarify dosage boundaries, response rates, and tolerability profiles.

Dr. Caplan’s Clinical Verdict: Preliminary and single-center findings must be interpreted within their exact methodological boundaries. While providing valuable mechanistic and observational signals, they do not replace individualized clinical counseling, careful titration, or established safety protocols.

1. Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis: A systematic review of randomized clinical trials.

Source: PubMed (2026Oct) | PMID: 42543771 | DOI: 10.1002/bcp.70719: Primary Link

Study Design & Cohort: This was a systematic review of randomized controlled trials evaluating natural and synthetic cannabinoids for multiple sclerosis related spasticity. The authors searched PubMed, EMBASE, and LILACS, and included 27 studies with more than 3000 participants treated with THC:CBD extracts, other cannabis extracts, isolated cannabinoids, or smoked cannabis. Two reviewers independently handled study selection, data extraction, and RoB 2 risk of bias assessment, with qualitative synthesis, pairwise random effects meta-analysis, and Bayesian network meta-analysis performed.

Primary Findings: In pairwise meta-analysis of 7 studies, THC:CBD extracts reduced patient reported spasticity versus placebo with a mean difference of -0.82, 95% CI -1.24 to -0.40, and I2 of 53%. Network meta-analysis confirmed benefit for THC:CBD extracts with a mean difference of -0.80 and 95% CrI -1.61 to -0.32, while adverse events were frequent but mostly mild to moderate and serious events were rare.

Clinical Relevance: In practice, THC:CBD products appear to offer modest symptom relief for MS spasticity, especially when the goal is patient reported functional improvement rather than a large objective change. I would consider them as adjunctive therapy in carefully selected patients, with attention to sedation, dizziness, cognitive effects, and additive interactions with other CNS active medications. The evidence base is low certainty, so dosing should be conservative, titrated slowly, and paired with close safety monitoring and clear functional goals.

2. Evidence for pro-cognitive benefits of cannabinoids in people with bipolar disorder.

Source: PubMed (2026Oct) | PMID: 42481733 | DOI: 10.1038/s41386-026-02489-w: Primary Link

Study Design & Cohort: This paper combines two human studies in bipolar disorder and healthy comparison adults. The first is an observational comparison of chronic cannabis users and non-users, and the second is a randomized clinical trial of acute delta-9-tetrahydrocannabinol (THC) versus placebo in non-cannabis-using participants with bipolar disorder and healthy controls. Participants completed the Temporal Discrimination Task and the 5-Choice Continuous Performance Task to assess timing, attention, and inhibitory control.

Primary Findings: In the chronic use study, bipolar disorder participants without cannabis use had significantly less precise timing than the other groups, while bipolar disorder participants with cannabis use showed temporal discrimination performance comparable to non-user healthy controls. The same pattern was seen for attention and inhibitory control on the 5-Choice Continuous Performance Task, where bipolar disorder cannabis users performed comparably to non-user healthy controls, while non-user bipolar disorder participants did not. In the acute trial, bipolar disorder participants given THC showed faster timing than placebo-treated healthy controls.

Clinical Relevance: From a practical standpoint, these findings fit the common clinical story of patients with bipolar disorder using cannabis to quiet racing thoughts and improve concentration. The signal here is that cannabinoid exposure may transiently improve timing and attention-related performance in some patients, so I would think carefully about symptom targets, dose, route, and psychiatric risk before dismissing the behavior outright. In real-world care, this also raises the question of whether standardized cannabinoid-based treatments could one day be studied for cognitive symptoms in bipolar disorder, while keeping a close eye on mood destabilization, sedation, and interactions with other psychotropics.

3. The Impacts of Marijuana Usage on Nerve Transfer Outcomes: A Retrospective Cohort Study.

Source: PubMed (2026Oct) | PMID: 42770158 | DOI: 10.1227/neuprac.0000000000000297: Primary Link

Study Design & Cohort: This was a retrospective cohort study from a single institution that reviewed adults age 18 years and older who underwent radial-to-axillary or ulnar fascicle to biceps fascicle (Oberlin) nerve transfer between 2014 and 2023. The analysis included 49 patients and 67 surgeries, with data collected on demographics, injury features, marijuana use, operative details, and Medical Research Council strength scores from preoperative assessment through 24 months after surgery.

Primary Findings: Marijuana use was not associated with achieving functional strength at 6, 12, 18, or 24 months after surgery, and this held true after controlling for procedure type. Patients who improved between 6 and 24 months, and those who improved from preoperative status to 24 months, were younger, with significant differences at P =.03 and P =.001, respectively. Patients who achieved functional strength by 24 months had a shorter injury-to-surgery interval, 0.7 ± 0.3 years versus 1.7 ± 2.5 years, P =.01.

Clinical Relevance: For my practice, this suggests marijuana use alone should not be used to predict poor motor recovery after radial-to-axillary or Oberlin nerve transfer. The bigger levers for outcome are timing and patient age, so I would still push for early referral and timely reconstruction when the anatomy and injury pattern allow it. When counseling patients who use cannabis for pain, I would focus more on perioperative planning, sedation considerations, and overall rehabilitation adherence than on expecting worse strength recovery from the cannabis exposure itself.

4. Evidence-based atlas of risk and protective factors for psychotic disorders: an umbrella review to inform personalized prognosis and prevention.

Source: PubMed (2026Oct) | PMID: 42742591 | DOI: 10.1002/wps.70093: Primary Link

Study Design & Cohort: This was a pre-registered umbrella review of systematic reviews and meta-analyses of observational studies published from February 1, 2017 through March 31, 2025. The authors included 69 reviews covering 970 individual studies and 221 candidate risk or protective factors for non-organic psychotic disorders diagnosed by ICD or DSM criteria, and they graded evidence using standardized umbrella review classes with AMSTAR quality assessment.

Primary Findings: Six factors met convincing class I evidence: Black-African ethnicity in England (OR 4.89, 95% CI 4.04 to 5.92), South Asian ethnicity in England (OR 2.15, 95% CI 1.69 to 2.73), paternal age under 20 years (OR 1.34, 95% CI 1.20 to 1.50), birthweight under 2,000 g (OR 1.77, 95% CI 1.48 to 2.13), birthweight under 2,500 g (OR 1.50, 95% CI 1.38 to 1.64), and maternal history of three or more previous pregnancies (OR 1.32, 95% CI 1.20 to 1.45). Eighteen additional factors were highly suggestive, including maternal psychosis, maternal mental health disorder, first-generation immigrant status, cannabis use 5 to 7 days per week, Toxoplasma gondii IgG positivity, ADHD history, and several minor physical anomaly measures, while the largest population attributable fractions were childhood adversities at 40.69%, Toxoplasma gondii IgG positivity at 20.47%, cannabis use 5 to 7 days per week at 12.75%, and clinical high-risk state at 12.68%.

Clinical Relevance: For clinic, this paper supports a more structured psychosis risk history that includes perinatal factors, family psychiatric history, immigration and ethnic context, cannabis exposure, and developmental markers such as ADHD or minor neurologic signs. The strongest modifiable targets are childhood adversity and frequent cannabis use, so I would use these data to justify early prevention work, substance counseling, and closer monitoring in high-risk patients, especially those in CHR-P states. The findings also reinforce the value of coordinated care with obstetrics, pediatrics, and primary care when low birthweight or other early-life risks are present, since these patients may benefit from earlier surveillance and referral pathways.

5. Improvement in Substance Use and Quality of Life in Patients Engaged in a Peer Navigator Program for Opioid Use Disorder.

Source: PubMed (2026Oct) | PMID: 42721628 | DOI: 10.1016/j.jemermed.2026.07.020: Primary Link

Study Design & Cohort: This was a retrospective review of patients enrolled in an emergency department based peer navigator program for opioid use disorder, using self-reported SAMHSA GPRA data collected from January 2021 to January 2022. Patients were enrolled during an initial ED visit and followed at 30 days, 90 days, and 1 year, with complete substance use data available for 80 patients and quality of life data for 79 patients.

Primary Findings: Opioid use fell from 63.8% at intake to 23.4% at 6 months (p < 0.0001), and overall illegal drug use declined from 73.8% to 32.8% (p < 0.0001). Marijuana use decreased from 31.3% to 14.1% (p = 0.004), alcohol use from 40% to 28.1% (p = 0.047), cocaine use from 26.3% to 6.3% (p = 0.0003), and criminal activity reports dropped from 72.2% to 32.8% (p < 0.001). ED utilization for substance related complaints declined from 41.8% to 3.1% (p < 0.0001), outpatient treatment engagement decreased from 81% to 18.8% (p < 0.0001), and satisfaction with living conditions, health, and relationships improved significantly.

Clinical Relevance: For patients with OUD who cycle through the ED, a peer navigator model can be a practical bridge to lower substance use, fewer substance related ED visits, and better day to day functioning. In real-world care, this kind of program fits well alongside MOUD initiation, harm reduction counseling, and referral support, especially when social instability is driving repeat utilization. I would view this as a useful adjunct for patients who need hands on follow up, care coordination, and help staying connected after the ED encounter.

6. Health and behavioural risks for adverse pregnancy and offspring outcomes across peak male fertility: Prevalence in the Australian longitudinal study on male health.

Source: PubMed (2026Oct) | PMID: 42685502 | DOI: 10.1016/j.puhe.2026.106466: Primary Link

Study Design & Cohort: This was a descriptive, cross-sectional analysis of a national cohort, using four waves of the Australian Longitudinal Study on Male Health collected from 2012 to 2022. The sample included fertile men aged 18 to 44 years at each wave, with wave-specific sample sizes of 8,727, 5,854, 3,267, and 2,705. Eleven preconception risk factors were assessed, including harmful alcohol use, cigarette use, cannabis use, illicit drug use, occupational exposure to harmful substances, type 2 diabetes, depression, high body mass, anxiety, intimate partner violence perpetration, and low fruit or vegetable intake.

Primary Findings: Across waves, 82% to 84% of men had at least one preconception risk factor, and 48% to 53% had two or more concurrent risks. Low fruit or vegetable intake was the most common exposure, affecting 76% to 77% of men. Compared with their peers, men under financial stress had 45% to 50% more risk factors, men with lower education had 18% to 30% more, unemployed men had 19% to 32% more, and men living in regional or remote areas had 12% to 22% more.

Clinical Relevance: From a preconception care standpoint, these data tell me that most reproductive-age men are entering conception with at least one modifiable risk factor, and many carry several at once. In practice, I would screen early for nutrition, substance use, weight, mood, and occupational exposures, then tailor counseling to social context, especially financial strain, unemployment, and lower educational attainment. This is the kind of population where brief intervention, referral, and practical lifestyle support before conception can matter for both fertility and downstream pregnancy outcomes.

7. Erectile dysfunction and subsequent substance abuse: a retrospective cohort study of US non-academic hospitals.

Source: PubMed (2026Oct) | PMID: 42666794 | DOI: 10.1093/sexmed/qfag059: Primary Link

Study Design & Cohort: This was a retrospective cohort study using the TriNetX database of US non-academic hospitals, with adult men diagnosed with erectile dysfunction (ICD-10 N52) and at least 3 years of follow-up. Patients were propensity-matched 1:1 to controls on age and race, then stratified into age groups 20 to 39, 40 to 64, and 65 years or older. Cox proportional hazards models were used to assess the 3-year risk of any substance abuse or dependence diagnosis (ICD-10 F10 to F19) and individual substance categories.

Primary Findings: The study included 323,838 men, 161,919 with erectile dysfunction and 161,919 controls. In men 65 years or older, erectile dysfunction was associated with higher risk of sedative abuse or dependence (HR 2.28, 95% CI 1.52 to 3.42, P <.001), other psychoactive substances (HR 1.79, 95% CI 1.43 to 2.24), opioids (HR 1.58, 95% CI 1.27 to 1.95), cocaine (HR 1.60, 95% CI 1.26 to 2.04), and cannabis (HR 1.45, 95% CI 1.10 to 1.92). The same older cohort had lower overall substance abuse risk (HR 0.86, 95% CI 0.82 to 0.89), driven by reduced nicotine dependence (HR 0.71, 95% CI 0.68 to 0.75), while men 40 to 64 years had increased cannabis risk (HR 1.32, P =.013) and other psychoactive substance risk (HR 1.21, P =.031), and men 20 to 39 years had lower opioid risk (HR 0.53, P =.020) and stimulant risk (HR 0.35, P =.003).

Clinical Relevance: In my practice, ED in an older man should prompt a careful substance use screen, especially for sedatives, opioids, cocaine, and cannabis, because the signal here is strongest in the 65-plus group. I would also review alcohol, nicotine, and psychoactive medication exposure, since these diagnoses may reflect prescribing patterns, self-medication, or comorbid mood and sleep disorders. For men with ED, age-specific counseling and follow-up can be built into the visit, with attention to drug interactions, sedation burden, and functional goals that matter to the patient.

8. Prevalence, determinants and trends of anabolic-androgenic steroid use among 93,437 high-school students: Repeated cross-sectional studies in Italy.

Source: PubMed (2026Oct) | PMID: 42664874 | DOI: 10.1016/j.puhe.2026.106470: Primary Link

Study Design & Cohort: This was a repeated representative cross-sectional study using annual ESPAD®Italia surveys from 2017 to 2023, excluding 2020. The analysis included 93,437 Italian adolescents aged 15 to 19 years, and lifetime anabolic-androgenic steroid use was examined with unconditional multiple logistic regression models.

Primary Findings: Lifetime AAS use prevalence was 1.9% overall, and current use was 0.8%. Lifetime use declined from 2.4% in 2017 to 1.2% in 2021, then increased to 3.3% in 2023. Higher odds of lifetime use were seen in males (OR 1.94, 95% CI 1.75 to 2.15), those preferring not to disclose gender (OR 4.18, 95% CI 3.00 to 5.81), overweight or obese adolescents (OR 1.27, 95% CI 1.10 to 1.46), and teens with daily, moderate, intense, or agonistic physical activity, with ORs of 1.21, 1.22, 1.74, and 1.29, respectively. Strong associations were also reported for slimming substances (OR 15.61, 95% CI 13.01 to 18.73), supplements (OR 4.59, 95% CI 4.07 to 5.19), cigarettes (OR 2.26, 95% CI 2.04 to 2.51), cannabis (OR 3.16, 95% CI 2.83 to 3.52), alcohol (OR 1.71, 95% CI 1.53 to 1.91), energy drinks (OR 4.25, 95% CI 3.81 to 4.74), gambling (OR 1.98, 95% CI 1.72 to 2.28), low school performance (OR 1.49, 95% CI 1.17 to 1.90), low self-satisfaction (OR 1.57, 95% CI 1.36 to 1.82), and social problems (OR 1.61, 95% CI 1.40 to 1.84).

Clinical Relevance: In my practice, this pattern says AAS use in teens tracks with broader risk behavior, body image distress, and performance pressure, so screening should extend beyond sports participation alone. I would ask directly about supplements, slimming products, energy drinks, tobacco, cannabis, alcohol, and gambling, because these exposures cluster with steroid use and can guide a more complete risk assessment. For counseling, the highest-yield intervention is early, nonjudgmental screening in adolescents with weight concerns, intense training, school difficulties, or social distress, with attention to gender-diverse youth and families who may need targeted education.

9. Cannabis use and associated sleep-disordered breathing among US adults.

Source: PubMed (2026Oct) | PMID: 42637625 | DOI: 10.1016/j.sleh.2026.07.003: Primary Link

Study Design & Cohort: This was a cross-sectional analysis of 14,485 US adults from the 2017 to 2018 Behavioral Risk Factor Surveillance System, using state-administered telephone survey data. Investigators used survey-weighted multivariable logistic regression to assess the association between self-reported cannabis use frequency and two sleep-disordered breathing markers, witnessed apnea during sleep and loud snoring.

Primary Findings: Cannabis use was reported in 5.5% of the cohort, and sleep-disordered breathing signs were reported in 44.7%. Compared with no cannabis use, non-regular use was associated with witnessed apnea during sleep (OR 1.41, 95% CI 1.05 to 1.86), loud snoring (OR 1.26, 95% CI 1.01 to 1.57), and either sign (OR 1.33, 95% CI 1.07 to 1.65), while regular use showed stronger associations for witnessed apnea (OR 1.73, 95% CI 1.27 to 2.33), loud snoring (OR 1.68, 95% CI 1.32 to 2.14), and either sign (OR 1.82, 95% CI 1.43 to 2.33). Each additional day of cannabis use per month was associated with higher odds of witnessed apnea, loud snoring, and either sleep-disordered breathing sign.

Clinical Relevance: In practice, I would treat frequent cannabis use as a potential contributor to snoring and witnessed apneas, especially in patients who already have obesity, daytime sleepiness, or other obstructive sleep apnea risk factors. When I counsel patients, I ask about route of use, timing relative to sleep, and co-use of alcohol or sedatives, since these factors can affect upper airway tone and sleep quality. For patients with suspected sleep-disordered breathing, cannabis history belongs in the same conversation as CPAP adherence, weight management, and formal sleep testing.

10. Ubiquitin-proteasome-dependent degradation of HIF-1α by cannabidiol disrupts pro-angiogenic synoviocyte-endothelial crosstalk in rheumatoid arthritis.

Source: PubMed (2026Oct) | PMID: 42542056 | DOI: 10.1016/j.phymed.2026.158661: Primary Link

Study Design & Cohort: This study used an adjuvant-induced arthritis rat model to test cannabidiol (CBD) in vivo, with arthritis scoring, micro-CT, histopathology, immunohistochemistry, and immunofluorescence. It also used rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) and HUVEC coculture experiments in vitro, with CBD concentrations of 2.4 to 4.8 μM for cell studies and 5 to 10 mg/kg for animal treatment. Mechanistic work included CCK-8 cytotoxicity testing, conditioned medium transfer, Western blotting, RT-qPCR, ELISA, co-immunoprecipitation, molecular docking, and MG132 proteasome inhibition.

Primary Findings: In AIA rats, CBD at 5 and 10 mg/kg markedly reduced joint inflammation, synovial angiogenesis, and structural bone destruction. In RA-FLS, non-cytotoxic CBD concentrations significantly suppressed proliferation, migration, invasion, and pro-inflammatory cytokine secretion, while also lowering VEGFA and ANG-2 release in a dose-dependent manner. CBD reduced hypoxia-induced HIF-1α protein accumulation without changing HIF1A mRNA, and MG132 reversed this effect, supporting ubiquitin-proteasome-dependent degradation of HIF-1α. Conditioned medium from CBD-treated RA-FLS impaired HUVEC migration, capillary-like tube formation, and VEGFR2 Tyr1175 phosphorylation.

Clinical Relevance: From a practical rheumatology perspective, this points to CBD as a candidate disease-modifying anti-angiogenic strategy for RA, with effects that extend beyond symptom control to synovial vascular signaling. The doses used in this preclinical work, 5 to 10 mg/kg in rats and 2.4 to 4.8 μM in cells, are not directly translatable to routine human prescribing, but they give a biologic range for future formulation and dosing studies. For patients already using cannabinoids, I would think about this as a mechanistic signal that CBD may influence synovial inflammation and endothelial activation, while still needing careful attention to product quality, hepatic metabolism, and interactions with other RA therapies.

11. The CB1 receptor as a convergence hub linking stress, sleep and appetite regulation: An integrative neurobiological model.

Source: PubMed (2026Oct) | PMID: 42431566 | DOI: 10.1016/j.neubiorev.2026.106863: Primary Link

Study Design & Cohort: This is a conceptual integrative neurobiological review, not a clinical trial or cohort study. The authors synthesize evidence from neuroendocrinology, chronobiology, and cannabinoid pharmacology to propose a model linking CB1 receptor signaling with stress, sleep, feeding behavior, and energy metabolism. Compounds discussed include anandamide (AEA), 2-arachidonoylglycerol (2-AG), Δ9-tetrahydrocannabinol (Δ9-THC), cannabigerol (CBG), noladin ether, and the enzymes FAAH and MAGL.

Primary Findings: The review proposes that stress-related HPA-axis activation changes AEA and 2-AG availability, which in turn alters stress responsivity and feeding behavior. Sleep restriction and circadian disruption are associated with altered endocannabinoid timing, increased hunger, stronger preference for highly palatable foods, and greater metabolic vulnerability. The authors also describe dose- and context-dependent effects of CB1-modulating ligands on POMC neurons, β-endorphin signaling, reward circuits, and UCP2-related mitochondrial adaptations.

Clinical Relevance: From a practical standpoint, this framework helps explain why patients with chronic stress, poor sleep, and appetite dysregulation often present with overlapping metabolic and mood symptoms. In my view, cannabinoid-based therapies need careful attention to dose, timing, and patient context, because CB1 effects can differ across sleep state, stress burden, and feeding phenotype. This model also supports a more individualized approach when considering cannabinoid exposure in patients taking other agents that affect appetite, mood, or energy balance.

12. Antiviral and anti-inflammatory effects of Cannabidiol in HIV/SIV infection.

Source: PubMed (2026Oct) | PMID: 42235652 | DOI: 10.1016/j.bbi.2026.106843: Primary Link

Study Design & Cohort: This was a translational preclinical study using rhesus macaques with acute SIV infection plus primary human immune cells and iPSC-derived human macrophages, T cells, and microglia. Cannabidiol was tested in the absence of ART and compared with first-line therapy effects on viral replication, reservoir establishment, and immune activation markers.

Primary Findings: CBD suppressed viral replication and reduced establishment of the viral reservoir in acute SIV-infected rhesus macaques to levels comparable with first-line therapies. In the macaques, CBD slowed CD4+ T cell decline, reduced CD14+CD16+ monocyte expansion, and lowered interferon-inducible cytokine release, with similar cytokine suppression seen in HIV-infected human macrophages, T cells, and microglia; CBD also inhibited NF-kB and STAT1 activation.

Clinical Relevance: From a practical standpoint, this supports CBD as a candidate adjunct for patients with HIV who remain inflamed despite ART, especially when immune activation is a functional concern. I would still treat this as preclinical evidence, so any real-world use should be cautious, with attention to product quality, dose consistency, and potential interactions with antiretrovirals and other CYP-metabolized medications. The signal that CBD dampened cytokines only when HIV triggered an immune response is clinically appealing, because it suggests a more targeted anti-inflammatory effect rather than broad immunosuppression.

13. ACMT Position Statement: Preventing Cannabis Exposures in Children (2026).

Source: PubMed (2026Oct) | PMID: 42684580 | DOI: 10.1007/s13181-026-01155-3: Primary Link

Study Design & Cohort: This is a 2026 American College of Medical Toxicology position statement based on expert review of the published literature and clinical toxicology experience. It addresses pediatric cannabis exposures, with emphasis on edible products, inhaled products, and accidental ingestion in children.

Primary Findings: The statement identifies pediatric cannabis exposure as a preventable toxicology problem, with edible products representing a major source of unintentional ingestion because of their appearance, packaging, and delayed onset of effects. It emphasizes that children can develop clinically significant CNS depression, ataxia, tachycardia, and altered mental status after exposure, and that severe cases may require emergency evaluation and supportive care.

Clinical Relevance: In practice, I treat this as a counseling and prevention issue every time I see families with cannabis in the home. I advise locked storage, child-resistant packaging, and clear separation of adult products from food or candy, especially with gummies, chocolates, and beverages that can be mistaken for snacks. For children with suspected exposure, clinicians should have a low threshold for poison center consultation and ED referral when there is lethargy, abnormal gait, respiratory concern, or persistent neurologic change.

14. Driving Under the Influence of Cannabis Among U.S. Young Adults Who Use Cannabis: Evidence From the 2021-2024 National Survey on Drug Use and Health.

Source: PubMed (2026Oct) | PMID: 42550121 | DOI: 10.1016/j.jadohealth.2026.05.015: Primary Link

Study Design & Cohort: This was a cross-sectional analysis of pooled 2021 to 2024 National Survey on Drug Use and Health data. The analytic sample included U.S. drivers aged 18 to 25 years who reported past-year cannabis use, with 17,141 unweighted respondents and a weighted population estimate of 10,814,381. The study examined self-reported past-year driving under the influence of cannabis using modified Poisson regression across demographics, substance use, mental health, cannabis-related perceptions, and driving behaviors.

Primary Findings: The weighted prevalence of driving under the influence of cannabis was 28.0%, which represented more than 3 million young adults. Compared with cannabis use on 1 to 11 days, adjusted prevalence ratios for DUIC rose with use frequency, from 2.51 for 12 to 49 days (95% CI, 2.29 to 2.75) to 3.63 for 300 to 365 days (95% CI, 3.60 to 3.76). Cannabis use disorder was associated with higher DUIC prevalence (APR, 2.34; 95% CI, 2.06 to 2.65), as were simultaneous alcohol and cannabis use (APR, 1.29; 95% CI, 1.28 to 1.30) and perceived easy cannabis availability (APR, 2.36; 95% CI, 2.33 to 2.39).

Clinical Relevance: In practice, I would treat frequent cannabis use, cannabis use disorder, and alcohol-cannabis co-use as clear red flags for impaired driving risk in young adults. Counseling should include explicit driving safety guidance, screening for substance use disorder, and a direct discussion of access, because perceived easy availability tracked with higher DUIC prevalence. For patients in states with medical cannabis laws, I would still counsel that legal access does not reduce driving impairment risk, and I would reinforce a no-driving-after-use plan.

15. Protective effect of cannabinoid type 2 receptor agonist (JWH-133) against ischemia/reperfusion injury.

Source: Life Sci (2026Oct) | PMID: 42730866 | DOI: 10.1016/j.lfs.2026.123567: Primary Link

Study Design & Cohort: This was a rat experimental study with 37 animals divided into four groups: control-sham (n = 9), Prangos ferulacea extract (n = 9), Prangos ferulacea extract plus JWH-133 (n = 9), and JWH-133 alone (n = 10). The investigators measured hepatic ER stress markers (CHOP, GRP78, ATF4), inflammatory mediators (IL-17, IL-23), HSP72, calpain, serum liver chemistries, histology, and caspase-3 immunohistochemistry after exposure to the plant extract and the CB2 agonist JWH-133.

Primary Findings: Hepatic GRP78, CHOP, ATF4, IL-17, and IL-23 did not differ significantly between groups, and serum IL-17 and IL-23 were also unchanged. Calpain differed across groups (P = 0.0017), with higher levels in the Prangos ferulacea group (P = 0.0325) and the combination group (P = 0.0076) versus control, while ALT, AST, albumin, and total protein were all lower in the Prangos ferulacea and combination groups compared with control, with P values of 0.0021, 0.0021, 0.0031, 0.0016, 0.0056, and 0.0017, respectively. Histopathologic injury was greatest in the Prangos ferulacea group versus control, JWH-133, and combination groups, all with P < 0.0001, and caspase-3 staining was intense in the Prangos ferulacea group but limited in the combination group.

Clinical Relevance: From a practical hepatology perspective, this model suggests that CB2 receptor activation with JWH-133 can blunt plant-induced liver injury even when classic ER stress markers stay unchanged. For clinicians, the signal is that cannabinoid pathway modulation may have hepatoprotective potential, but dosing, product purity, and drug interaction issues would need careful study before any patient use. I would view this as a mechanistic preclinical lead, with the strongest functional readout being preserved histology and reduced apoptosis rather than changes in cytokines or ER stress proteins.

The current research cohort reflects diverse investigations spanning Efficacy and safety of cannabinoids in the treatme, emphasizing rigorous study endpoints and reproducible methodologies across academic centers.

Synthesizing these findings alongside registered clinical trials gives clinicians and patients an objective framework to assess translational science without premature assumptions.

Tracking literature like Efficacy and safety of cannabinoids in the treatme is most valuable when we look past the excitement to the actual endpoints and patient population.

Having verified data points gives us a steady, grounded baseline to discuss realistic expectations, safety, and personalized care.

Three Rules for Critical Reading